Abstract

Aldesleukin still beats SC IL-2 + IFN-??-2b in metastatic renal cancer

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Immunotherapy for renal carcinoma: theoretical basis and current standard of care.
Paul A Vasey
British journal of clinical pharmacology | VOL. 50
Paul A VaseyPaul A Vasey
01 Dec 2000
Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. Identification of the Antigens Mediating Response
S.A Rosenberg ... S.M Steinberg
Investigative urology | VOL. 162
S.A Rosenberg, et. al.S.A Rosenberg ... S.M Steinberg
01 Aug 1999
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.
Steven A Rosenberg ... James C Yang
ANNALS of SURGERY | VOL. 228
Steven A Rosenberg, et. al.Steven A Rosenberg ... James C Yang
01 Sep 1998
Second-Line Therapy After VEGF Targeted Therapy in Metastatic Renal Cancer: A Law of Diminishing Returns
Thomas Powles
Clinical genitourinary cancer | VOL. 10
Thomas PowlesThomas Powles
17 May 2012
View more papers

More From: Inpharma Weekly

Paper Title
Journal
Date
Author
The Simpsons could describe the future of medical publishing
Inpharma Weekly | VOL. -
01 Dec 2008
I scream, you scream, we all scream for ice cream
&Na;
Inpharma Weekly | VOL. -
&Na; &Na;
01 Dec 2008
Universal HIV testing and immediate ART of benefit
Inpharma Weekly | VOL. -
01 Dec 2008
CERE 120 has failed to demonstrate any distinct benefit for patients with Parkinson's disease
&Na;
Inpharma Weekly | VOL. -
&Na; &Na;
01 Dec 2008
View more papers